PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-12 pm EDT
50.11 USD   +3.77%
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer and BioNTech SE Granted U.S. Emergency Use Authorization for Booster Dose of Their Covid-19 Vaccine in Children 5 Through 11 Years of Age

05/17/2022 | 11:40am EDT

Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration (FDA) expanded emergency use authorization (EUA) to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age. The booster dose is given at least five months after the second dose of the two-dose primary series and is the same 10-µg dose of the Pfizer-BioNTech COVID-19 Vaccine. To date, more than 8 million5- to 11-year-olds in the U.S. have completed primary series. The expanded EUA is based on data from the Phase 2/3 clinical trial, which showed that a booster dose of the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group, generating neutralizing antibodies against both the Omicron variant and wild-type SARS-CoV-2 virus regardless of prior SARS-CoV-2 infection. No new safety signals were observed. The third dose was well tolerated, with a safety profile similar to the two-dose primary series. This Phase 2/3 data builds on efficacy data for the primary two-dose series which showed 90.7% efficacy in children 5 through 11 without prior SARS-CoV-2 infection, measured from 7 days after the second dose, at a period when Delta was the prevalent strain. The companies have already submitted an application to the European Medicines Agency for a booster dose in this age group and are planning to file with other regulatory agencies around the world. The Pfizer-BioNTech COVID-19 Vaccine is the only COVID-19 vaccine authorized for use in the U.S. for children 5 through 11 years of age. The Phase 1/2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of a3-µg formulation of the Pfizer-BioNTech COVID-19 Vaccine on a three-dose schedule in children ages 6 months through 4 years (also known as under 5) is ongoing. Initial data is expected in the coming weeks.


© S&P Capital IQ 2022
All news about PFIZER, INC.
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/12Oncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational..
AQ
08/12There are two ways to see inflation data
MS
08/12Pfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Cov..
MT
08/12Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
BU
08/12Pfizer Inc. Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumoc..
CI
08/12GSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
08/12Haleon Says It Hasn't Been Notified About Litigation on Zantac Drug -- Update
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,89x
Yield 2022 3,23%
Capitalization 281 B 281 B -
EV / Sales 2022 2,65x
EV / Sales 2023 3,37x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 50,11 $
Average target price 56,53 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.14%281 235
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550